Cencora, Inc. (NYSE:COR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Cencora, Inc. (NYSE:COR) have been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $277.90.

COR has been the topic of a number of research analyst reports. Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. Barclays upped their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Robert W. Baird raised their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company upped their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th.

Cencora Price Performance

NYSE COR opened at $247.94 on Friday. The company has a 50-day moving average price of $239.01 and a two-hundred day moving average price of $236.57. Cencora has a 52 week low of $214.77 and a 52 week high of $262.26. The stock has a market cap of $47.92 billion, a price-to-earnings ratio of 33.01, a price-to-earnings-growth ratio of 1.59 and a beta of 0.49. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 266.62% and a net margin of 0.51%. Analysts forecast that Cencora will post 15.32 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend is Friday, February 14th. Cencora’s dividend payout ratio is presently 29.29%.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares in the company, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock valued at $17,790,912 over the last three months. Company insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

Several institutional investors and hedge funds have recently bought and sold shares of COR. Czech National Bank increased its stake in shares of Cencora by 12.6% in the third quarter. Czech National Bank now owns 35,536 shares of the company’s stock worth $7,998,000 after acquiring an additional 3,990 shares during the last quarter. Dynamic Advisor Solutions LLC increased its position in Cencora by 15.2% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock worth $262,000 after purchasing an additional 154 shares during the last quarter. LVW Advisors LLC raised its stake in shares of Cencora by 14.2% during the 3rd quarter. LVW Advisors LLC now owns 3,666 shares of the company’s stock worth $825,000 after purchasing an additional 456 shares in the last quarter. Iowa State Bank acquired a new stake in shares of Cencora during the 3rd quarter valued at about $1,390,000. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in shares of Cencora by 33.7% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 27,375 shares of the company’s stock valued at $6,160,000 after buying an additional 6,900 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.